PMV Pharmaceuticals, Inc. (PMVP) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Princeton, NJ, United States. The current CEO is David H. Mack.
PMVP has IPO date of 2020-09-25, 47 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $78.39M.
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.
